Literature DB >> 6786003

Prevalence of dementia disorders in institutionalized Swedish old people. The work load imposed by caring for these patients.

R Adolfsson, C G Gottfries, L Nyström, B Winblad.   

Abstract

The prevalence of dementia disorders were determined among 3,523 institutionalized patients aged 65 years or more in the county of Västerbotten. Approximately one-third of the clientele were considered demented. The prevalence was calculated to be 3.7% of the population in the county. The frequency of dementia disorders among the patients in the somatic long-stay wards, the nursing homes, and the mental hospital was rather similar (55-65%). A surprisingly high percentage of demented (17.1%) was found in the homes for the aged. The work load was highest in the somatic long-stay wards and in the nursing homes. Patients in the mental hospital, however, differed markedly from those in other institutions with higher scores for aggressive and disturbing behaviour, which accounted for the large number of patients in the mental hospital with maximal work load. The findings are discussed with regard to future institutional care of demented patients and point out the need for better education in psychiatric care for the staff.

Entities:  

Mesh:

Year:  1981        PMID: 6786003     DOI: 10.1111/j.1600-0447.1981.tb00670.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  21 in total

1.  Aluminium and Alzheimer's disease: An epidemiological approach.

Authors:  C N Martyn
Journal:  Environ Geochem Health       Date:  1990-03       Impact factor: 4.609

2.  Reduction in the use of potentially inappropriate drugs among old people living in geriatric care units between 2007 and 2013.

Authors:  Maria Gustafsson; Per-Olof Sandman; Stig Karlsson; Ulf Isaksson; Jörn Schneede; Maria Sjölander; Hugo Lövheim
Journal:  Eur J Clin Pharmacol       Date:  2015-02-26       Impact factor: 2.953

3.  Cholecystokinin peptides and receptor binding in Alzheimer's disease.

Authors:  C Löfberg; J Harro; C G Gottfries; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden.

Authors:  Sofia Svahn; Hugo Lövheim; Ulf Isaksson; Per-Olof Sandman; Maria Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2020-01-08       Impact factor: 2.953

5.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

Authors:  M Landén; A Thorsell; A Wallin; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  Brain metabolism in Alzheimer's dementia: studies of 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects.

Authors:  H Nybäck; H Nyman; G Blomqvist; I Sjögren; S Stone-Elander
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 7.  Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

Authors:  C G Gottfries
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

Authors:  K Blennow; N Bogdanovic; I Alafuzoff; R Ekman; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Synapsin I (protein I) in different brain regions in senile dementia of Alzheimer type and in multi-infarct dementia.

Authors:  E Perdahl; R Adolfsson; I Alafuzoff; K A Albert; E J Nestler; P Greengard; B Winblad
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

10.  Muscarinic receptor compensation in hippocampus of Alzheimer patients.

Authors:  A Nordberg; C Larsson; R Adolfsson; I Alafuzoff; B Winblad
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.